Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7537525 | 0.89 | AOC3 (0.46) | AOC3HSD17B10 | |
| SCHEMBL8225111 | 0.82 | AOC3 (0.50) | AOC3HSD17B10CYP1A2 | |
| SCHEMBL7112651 | 0.81 | CYP1A2 (0.42) | HSD17B10CYP1A2CYP2C9P4HTMNPSR1 | |
| SCHEMBL18782928 | 0.78 | CYP1A2 (0.43) | HSD17B10CYP1A2CYP2C9P4HTMPLAU | |
| SCHEMBL889024 | 0.77 | HRH4 (0.55) | HSD17B10CYP1A2CYP2C9P4HTMNPSR1 | |
| SCHEMBL3396659 | 0.77 | CYP1A2 (0.42) | HSD17B10CYP1A2CYP2C9P4HTMPLAU | |
| SCHEMBL18071081 | 0.75 | GRIA1 (0.46) | AOC3CYP1A2CYP2C9 | |
| SCHEMBL5201259 | 0.74 | PDE9A (0.40) | HSD17B10CYP1A2CYP2C9P4HTMNPSR1 | |
| SCHEMBL13095827 | 0.73 | SLC7A5 (0.54) | AOC3HSD17B10CYP1A2CYP2C9NPSR1 | |
| SCHEMBL3696353 | 0.72 | QPCT (0.55) | AOC3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20220402896-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-12-22 | — | — | US | disclosed |
| US-20220162194-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11124497-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTSV, CTRL, CTSL | AOC3 2019/4885HSD17B10 966/4885CYP1A2 792/4885 |
| US-20220162194-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | AOC3 2019/4885HSD17B10 966/4885CYP1A2 792/4885 |
| US-20220402896-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | AOC3 2019/4885HSD17B10 966/4885CYP1A2 792/4885 |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | AOC3 2046/4885HSD17B10 1711/4885CYP1A2 2410/4885 |
| US-11124497-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | AOC3 1928/4885HSD17B10 1706/4885CYP1A2 1674/4885 |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | AOC3 2046/4885HSD17B10 1711/4885CYP1A2 2410/4885 |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | AOC3 2019/4885HSD17B10 966/4885CYP1A2 792/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | AOC3 1873/4885HSD17B10 1162/4885CYP1A2 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.